.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,791,154

« Back to Dashboard

Claims for Patent: 8,791,154

Title:High concentration olopatadine ophthalmic composition
Abstract: The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.
Inventor(s): Gamache; Daniel A. (Arlington, TX), Alani; Laman (Fort Worth, TX), Ghosh; Malay (Fort Worth, TX), Galan; Francisco Javier (Barcelona, ES), Perdiguer; N ria Carreras (Barcelona, ES), Singh; Onkar N. (Arlington, TX)
Assignee: Alcon Research, Ltd. (Fort Worth, TX)
Application Number:13/475,607
Patent Claims: 1. An aqueous ophthalmic solution for treatment of ocular allergic conjunctivitis, the solution comprising: at least 0.67 w/v % olopatadine dissolved in the solution; PEG having a molecular weight of 300 to 500; polyvinylpyrrolidone; hydroxypropyl-.gamma.-cyclodextrin; benzalkonium chloride; and water.

2. A solution as in claim 1 further comprising borate.

3. A solution as in claim 2 further comprising a polyol.

4. An aqueous ophthalmic solution for treatment of ocular allergic conjunctivitis, the solution comprising: at least 0.67 w/v % but no greater than 1.0 w/v % olopatadine dissolved in the solution; 2.0 w/v % to 6.0 w/v % PEG having a molecular weight of 300 to 500; 2.0 w/v % to 6.0 w/v % polyvinylpyrrolidone; at least 0.5 w/v % but no greater than 2.0 w/v % cyclodextrin derivative selected from the group consisting of SAE-.beta.-cyclodextrin, HP-.gamma.-cyclodextrin, HP-.beta.-cyclodextrin and combinations thereof; and water.

5. A solution as in claim 4 further comprising borate at a concentration of at least 0.18 w/v % but less than 0.5 w/v %.

6. A solution as in claim 5 further comprising a polyol.

7. A solution as in claim 6 wherein the polyol is propylene glycol at a concentration of at least 0.4 w/v % but no greater than 2.2 w/v %.

8. An aqueous ophthalmic solution for treatment of ocular allergic conjunctivitis, the solution comprising: at least 0.67 w/v % but no greater than 1.0 w/v % olopatadine dissolved in the solution; 2.0 w/v % to 6.0 w/v % PEG having a molecular weight of 300 to 500; 2.0 w/v % to 6.0 w/v % polyvinylpyrrolidone; at least 0.5 w/v % but no greater than 2.0 w/v % hydroxypropyl-.gamma.-cyclodextrin; and water.

9. A solution as in claim 8 further comprising borate at a concentration of at least 0.18 w/v % but less than 0.5 w/v %.

10. A solution as in claim 9 further comprising a polyol.

11. A solution as in claim 10 wherein the polyol is propylene glycol at a concentration of at least 0.4 w/v % but no greater than 2.2 w/v %.

12. A method of treating at least one ocular allergy symptom in humans, the method comprising: topically applying to an eye of a human an amount of the solution of claim 4 sufficient to treat the at least one ocular allergy symptom.

13. A method as in claim 12 wherein the step of topically applying the solution includes dispensing at least one drop of the solution to the eye.

14. A method as in claim 13 wherein the at least one ocular allergy symptom includes ocular itching.

15. A solution as in claim 1 further comprising hydroxypropylmethyl cellulose.

16. A solution as in claim 4 further comprising at least 0.15 w/v % but no greater than 1.0 w/v % hydroxypropylmethyl cellulose.

17. A solution as in claim 8 further comprising at least 0.15 w/v % but no greater than 1.0 w/v % hydroxypropylmethyl cellulose.

18. A solution as in claim 3 wherein the polyol is mannitol.

19. A solution as in claim 6 wherein the polyol is mannitol solution at a concentration that is at least 0.05 w/v % but no greater than 0.5 w/v %.

20. A solution as in claim 10 wherein the polyol is mannitol at a concentration that is at least 0.05 w/v % but no greater than 0.5 w/v %.

21. An aqueous ophthalmic solution for treatment of ocular allergic conjunctivitis, the solution comprising: at least 0.67 w/v % but no greater than 1.0 w/v % olopatadine dissolved in the solution; 2.0 w/v % to 6.0 w/v % PEG having a molecular weight of 300 to 500; 2.0 w/v % to 6.0 w/v % polyvinylpyrrolidone; at least 0.5 w/v % but no greater than 2.0 w/v % hydroxypropyl-.gamma.-cyclodextrin; greater than 0.003 w/v % but less than 0.03 w/v % benzalkonium chloride; and water; wherein the pH of the solution is 6.0 to 7.8 and the osmolality of the solution is 200 to 400 mOsm/kg.

22. A solution as in claim 21 further comprising at least 0.15 w/v % but no greater than 1.0 w/v % hydroxypropylmethyl cellulose.

23. A solution as in claim 22 wherein: i) the concentration of PEG is at least 3.0 w/v % but no greater than 5.0 w/v %; ii) the concentration of polyvinylpyrrolidone is at least 3.0 w/v % but no greater than 5.0 w/v %; and iii) the concentration of hydroxypropyl methylcellulose is at least 0.3 w/v % but no greater than 0.5 w/v %.

24. A solution as in claim 23 further comprising: at least 0.18 w/v % but less than 0.4 w/v % boric acid; and at least 0.05 w/v % but no greater than 0.5 w/v % mannitol.

25. A method of treating ocular allergy symptoms in humans, the method comprising: topically applying to an eye of a human an amount of the solution of claim 23 sufficient to treat ocular allergy symptoms.

26. A method as in claim 25 wherein the step of topically applying the solution includes dispensing at least one drop of the solution to the eye.

27. A method as in claim 26 wherein the ocular allergy symptoms include ocular itching.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc